Mark A. Velleca, M.D., Ph.D., born in 1973, is the current CEO of Black Diamond Therapeutics, Inc., a biotech firm he joined in September 2023. His background is impressive, with a medical degree and Ph.D. from Washington University in St....
Mark A. Velleca, M.D., Ph.D., born in 1973, is the current CEO of Black Diamond Therapeutics, Inc., a biotech firm he joined in September 2023. His background is impressive, with a medical degree and Ph.D. from Washington University in St. Louis. He has a rich history in the biotech world, including previous roles as CEO of G1 Therapeutics from 2014 to 2021 and as a senior advisor to major companies like Gilead Sciences. Dr. Velleca has been part of the board at Black Diamond since 2021, becoming its Chair in December 2022. His leadership track record shows a focus on achieving corporate goals and managing complex projects in drug development. Interestingly, he recently resigned from the Board of G1 Therapeutics but continues to work closely with the company as a senior advisor until the end of 2024. This reflects his strong commitment and influence within the biotech field, proving that his expertise is highly valued. In 2023, he earned about $1.18 million, combining salary and bonuses, showing how his performance is closely tied to the company’s success.